BridgeBio Pharma Reports Q2 2026 Results and Business Update

What Happened
BridgeBio Pharma, Inc. filed a Form 8-K on August 10, 2026 to announce recent business updates and its financial results for the second quarter ended June 30, 2026. The company furnished a press release announcing the results as Exhibit 99.1 to the 8-K. The filing is signed by Thomas Trimarchi, Ph.D., President and Chief Financial Officer.

Key Details

• Form 8-K filed: August 10, 2026 (Item 2.02 — Results of Operations and Financial Condition).
• Reporting period: Quarter ended June 30, 2026 (Q2 2026).
• Press release announcing the results furnished as Exhibit 99.1 to the 8-K.
• Filing signed by Thomas Trimarchi, Ph.D., President & CFO; interactive XBRL cover page included (Exhibit 104).

Why It Matters
This 8-K signals that BridgeBio has publicly released its quarterly results and business updates—information investors use to assess earnings, revenue, R&D progress, cash position and program milestones. Retail investors should read the press release (Exhibit 99.1) for the specific financial figures and business developments, and expect the company’s next periodic filings (e.g., the Form 10-Q) for detailed financial statements and management discussion.